AdjuCor Raises € 29 Million in Series B Funding Round for its Revolutionary Heart Assist Technology that Completely Avoids Blood Contact
Share Article
AdjuCor raises € 29 million to enable its next phase of bringing its revolutionary heart assist technology to the severely underserved end-stage heart failure patients. This Series B financing round includes € 25 million from the cardiovascular-focused medical device platform company MitrAssist Holdings Limited accompanied by an additional € 4 million from the returning investor Maurizio Group.
AdjuCor s revolutionary technology provides mechanical circulatory support without blood contact. It is achieved by gently squeezing the outer surface of the heart, in sync with its natural rhythm.